New Market Entrants and Price Competition
First written in FY2016. 25 of 26 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2026: 31 of 91 companies on the "Worse" side.
121 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「The group seeks to differentiate itself from other companies and achieve sustained business growth by leveraging its healthcare-related database, claims analysis technologies, and business partners' strengths to create new services. However, if competitors erode the group's competitive advantage, price competition could intensify and affect the group's business performance and future business development.」
The company reconfirms the risks of competitor entry and price competition, as well as countermeasures leveraging its database, analytical technologies, and business partners' strengths. - FY2024RestatedAnnual report
「The market for the group's healthcare business is expected to continue expanding, but competitors with business models that partially overlap with the group's business model exist.」
The company reconfirms the existence of competitors and the risk of intensified price competition if its competitive advantage is lost. It identifies developing new services, improving existing services, and creating new services with business partners as countermeasures. - FY2024-Q3RestatedAnnual report
「No new business or other risks arose during the nine months ended 31 December. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The company states that there have been no new developments or material changes regarding existing business and other risks, including competitor entry and price competition. - FY2024-Q2RestatedAnnual report
「No new business or other risks arose during the first half of the current consolidated fiscal year. In addition, no material changes have occurred in the business and other risks described in the securities report for the previous fiscal year.」
The company states that there have been no new developments or material changes regarding existing business and other risks, including competitor entry and price competition. - FY2024-Q1RestatedAnnual report
「No new business or other risks arose during the three months ended 30 June. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The company states that there have been no new developments or material changes regarding existing risks, including competitor entry and price competition. - FY2023-Q2RestatedAnnual report
「No new business or other risks arose during the six months ended 30 September. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The company states that there have been no new developments or material changes regarding existing business and other risks, including competitor entry and price competition. - FY2023-Q1RestatedAnnual report
「During the first quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no new developments or material changes regarding existing business and other risks, including competitor entry and price competition. - FY2022-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no new developments or material changes regarding existing risks, including competitor entry and price competition. - FY2021RestatedAnnual report
「The group seeks to differentiate itself from other companies and achieve sustained business growth through its healthcare-related database, developed over many years, and four patented claims analysis technologies. However, if competitors erode the group's competitive advantage, price competition could intensify and affect the group's business performance and future business development.」
The company reconfirms the risks of competitor entry and price competition, as well as differentiation based on four patented claims analysis technologies. - FY2021-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company reconfirms that there have been no new developments or material changes regarding existing business and other risks, including competitor entry and price competition. - FY2021-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company disclosed that there had been no new developments or material changes regarding the risks of competitor entry and price competition. - FY2021-Q1RestatedAnnual report
「During the first quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company reconfirms that there have been no new developments or material changes regarding the risks of competitor entry and price competition. - FY2020RestatedAnnual report
「The group seeks to differentiate itself from other companies and achieve sustained business growth through its healthcare-related database, developed over many years, and four patented claims analysis technologies. However, if competitors erode the group's competitive advantage, price competition could intensify and affect the group's business performance and future business development.」
The company reconfirms the risks of competitor entry and price competition, identifying four patented claims analysis technologies as the basis for its differentiation. - FY2020-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company disclosed that there had been no new developments or material changes regarding the risks of competitor entry and price competition. - FY2019RestatedAnnual report
「The market for the group's healthcare-related information services is expected to continue expanding, but competitors offering business models that partially overlap with the group's business model have emerged.」
The company reconfirms the emergence of competitors and the risk of intensified price competition if its competitive advantage is lost. - FY2019-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company disclosed that there had been no new developments or material changes regarding the risks of competitor entry and price competition. - FY2019-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company disclosed that there had been no new developments or material changes regarding the risks of competitor entry and price competition. - FY2019-Q1RestatedAnnual report
「During the first quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company disclosed that there had been no new developments or material changes regarding the risks of competitor entry and price competition. - FY2018RestatedAnnual report
「The market for the group's healthcare-related information services is expected to continue expanding, but competitors offering business models that partially overlap with the group's business model have emerged.」
The company continues to describe competitor entry and the risk of price competition if its competitive advantage declines. - FY2018-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company disclosed that there had been no new developments or material changes regarding the risks of competitor entry and price competition. - FY2018-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company disclosed that there had been no new developments or material changes regarding the risks of competitor entry and price competition. - FY2018-Q1RestatedAnnual report
「During the first quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company disclosed that there had been no new developments or material changes regarding the risks of competitor entry and price competition. - FY2017RestatedAnnual report
「The group seeks to differentiate itself from other companies and achieve sustained business growth through its healthcare-related database, developed over many years, and three patented claims analysis technologies. However, if competitors erode the group's competitive advantage, price competition could intensify and affect the group's results and future business development.」
The company continues to describe the risks of competitor entry and price competition, identifying three patented technologies as the basis for its differentiation. - FY2017-Q3RestatedAnnual report
「During the cumulative third-quarter period, no new business or other risks arose. In addition, there were no significant changes to the business and other risks described in the securities report for the previous fiscal year.」
The company disclosed that there had been no new developments or material changes regarding the risks of competitor entry and price competition. - FY2016RestatedAnnual report
「The company seeks to differentiate itself from other companies and achieve sustained business growth through its healthcare-related database, developed over many years, and two patented claims analysis technologies. However, if competitors erode the company's competitive advantage, price competition could intensify and affect its results and future business development.」
The company continues to describe the risks of competitor entry and price competition, as well as differentiation based on its database and patented technologies. - FY2016First statedAnnual report
「The market for the company's healthcare-related information services is expected to continue expanding, but competitors offering business models that partially overlap with the company's business model have emerged.」
The company indicates that the emergence of competitors and intensified price competition could weaken its competitive advantage and affect its results and business development.